Avelumab use in Merkel cell carcinoma treatment

Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC. In March 2017, the FDA granted accelerated approval to avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) irrespective of prior therapy. In July 2017, the European Medicines Agency (EMA) recommended the approval of avelumab as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC). Approvals were based on the efficacy and safety demonstrated in JAVELIN Merkel 200 (NCT02155647), a multi-center, open-label, single-arm, phase II clinical trial [1]. Part A of the study consisted of patients treated in the second line with metastatic, chemotherapy-refractory MCC. Part B consisted of systemic treatment-naive patients who received avelumab as first-line treatment for metastatic or distally recurrent MCC. In the first line the ORR is 39.7%. Durable responses lasting at least 6 months were observed and the majority of responses are observed earlywith the median time to response of 6.1 week. PFS rate at 6 months and at 12 months are 41% and 31%, respectively. Median OS is 20.3 months. The OS rate at 1 year is 60%

Avelumab use in Merkel cell carcinoma treatment

Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC. In March 2017, the FDA granted accelerated approval to avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) –irrespective of prior therapy. In July 2017, the European Medicines Agency (EMA) recommended the approval of avelumab as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC). Approvals were based on the efficacy and safety demonstrated in JAVELIN Merkel 200 (NCT02155647), a multi-center, open-label, single-arm, phase II clinical trial [1]. Part A of the study consisted of patients treated in the second line with metastatic, chemotherapy-refractory MCC. Part B consisted of systemic treatment-naive patients who received avelumab as a first-line treatment for metastatic or distally recurrent MCC. In the first line the ORR is 39.7%. Durable responses lasting at least 6 months were observed and the majority of responses are observed early with the median time to response of 6.1 week. PFS rate at 6 and 12 months are 41% and 31%, respectively. Median OS is 20.3 months. The OS rate at 1 year is 60%

Annotated bibliography of the works of Roman Brandstaetter

Przedmiotem pracy jest dorobek twórczy Romana Brandstaetttera. Celem pracy jest sporządzenie bibliografii adnotowanej dzieł pisarza w oparciu o metodykę sporządzania spisów bibliograficznych i praktykę bibliograficzną. W pracy nakreślono sylwetkę Romana Brandstaettera oraz omówiono najważniejsze zagadnienia teoretyczne bibliografii, w tym pojęcie i podział bibliografii. Przedstawiono podstawowe rozwiązania stosowane w metodyce bibliograficznej, związane m.in. z wyborem układu zrębu głównego, metody szeregowania oraz tworzeniem spisów pomocniczych i materiałów wprowadzających. Na podstawie zgromadzonego materiału sporządzono bibliografię zawierającą 301 opisów bibliograficznych, zaopatrzoną w indeks osobowy, tytułowy oraz wykaz skrótów i tytułów czasopism.The subject of the master thesis is the work of Roman Brandstaetter. The aim of the work is to create an annotated bibliography by using bibliographic approach and practice. The paper presents life and work of Roman Brandstaetter and discusses the most important theoretical issues related to concept and division of bibliography. The basis solutions used in bibliographic approach related to choosing bibliography order, scheduling of bibliographic descriptions and creating auxiliary lists and introductory materials was presents. On the basis of collected material a bibliography containing 301 bibliographic descriptions and also name index, title index and title index of periodicals was made

Pareto Joint Inversion of 2D magnetometric and gravity data- synthetic study

Pareto joint inversion for two or more data sets is an attractive and promising tool which eliminates target functions weighing and scaling, providing a set of acceptable solutions composing a Pareto front. In former author’s study MARIA (Modular Approach Robust Inversion Algorithm) was created as a flexible software based on global optimization engine (PSO) to obtain model parameters in process of Pareto joint inversion of two geophysical data sets. 2D magnetotelluric and gravity data were used for preliminary tests, but the software is ready to handle data from more than two geophysical methods. In this contribution, the authors’ magnetometric forward solver was implemented and integrated with MARIA. The gravity and magnetometry forward solver was verified on synthetic models. The tests were performed for different models of a dyke and showed, that even when the starting model is a homogeneous area without anomaly, it is possible to recover the shape of a small detail of the real model. Results showed that the group analysis of models on the Pareto front gives more information than the single best model. The final stage of interpretation is the raster map of Pareto front solutions analysis

Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients

Gastrointestinal stromal tumors (GISTs) originate from Cajal’s cells and are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs in young adults, i.e., patients before the age of 40, are rare and differ from those in older patients and GISTs in children in terms of the molecular and clinical features, including the location and type of mutations. They often harbor other molecular abnormalities than KIT and PDGFRA mutations (wild-type GISTs). The general principles of therapeutic management in young patients are the same as in the elderly. Considering some differences in molecular abnormalities, molecular testing should be the standard procedure to allow appropriate systemic therapy if needed. The optimal treatment strategy should be established by a multidisciplinary team experienced in sarcoma treatment. The impact of treatment on the quality of life and daily activities, including the impact on work, pregnancy, and fertility, in this patient population should be especially taken into consideration